Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development Post published:February 16, 2021 Post category:Press Release
MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization Post published:February 16, 2021 Post category:Press Release
Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program Post published:February 16, 2021 Post category:Press Release
Psychedelics Research Review: January 2021 Post published:February 15, 2021 Post category:Psychedelics Research Review
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Post published:February 12, 2021 Post category:Press Release
ATMA Launches Canada’s First Psychedelic Training Program for Mental Health Professionals that Includes a Legal Psychedelic Experience Post published:February 12, 2021 Post category:Press Release
Psychedelic Bulletin: DMT for Stroke; MindMed’s Drug Discovery Partnership; Psychedelics are in Vogue Post published:February 12, 2021 Post category:Psychedelic Bulletin
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke Post published:February 11, 2021 Post category:Press Release
Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board Post published:February 11, 2021 Post category:Press Release